Table 3 Number of HCE (health care expenditures) incurred for each disease group
| Â | Time to death | ||||||||
|---|---|---|---|---|---|---|---|---|---|
Sex | Age Group | Disease Group | 6 | 5 | 4 | 3 | 2 | 1 | 0 |
Male | 65–75 | Circulatory1 | 5632 (4.6%) | 5717 (4.7%) | 5759 (4.7%) | 5817 (4.8%) | 5870 (4.8%) | 5910 (4.8%) | 5354 (4.4%) |
Respiratory | 3531 (2.9%) | 3610 (3.0%) | 3792 (3.1%) | 4028 (3.3%) | 4251 (3.5%) | 4732 (3.9%) | 4932 (4.0%) | ||
CKD | 691 (0.6%) | 710 (0.6%) | 723 (0.6%) | 741 (0.6%) | 758 (0.6%) | 780 (0.6%) | 698 (0.6%) | ||
Neoplasms | 3728 (3.0%) | 3891 (3.2%) | 4116 (3.4%) | 4327 (3.5%) | 4647 (3.8%) | 4990 (4.1%) | 4784 (3.9%) | ||
Others | 7850 (6.4%) | 7935 (6.5%) | 8040 (6.6%) | 8181 (6.7%) | 8314 (6.8%) | 8547 (7.0%) | 7983 (6.5%) | ||
75–85 | Circulatory | 14,111 (11.5%) | 14,144 (11.6%) | 14,232 (11.6%) | 14,130 (11.6%) | 14,206 (11.6%) | 14,164 (11.6%) | 12,744 (10.4%) | |
Respiratory | 8521 (7.0%) | 8850 (7.2%) | 9087 (7.4%) | 9503 (7.8%) | 10,333 (8.4%) | 11,574 (9.5%) | 11,936 (9.8%) | ||
CKD | 1881 (1.5%) | 1909 (1.6%) | 1950 (1.6%) | 1985 (1.6%) | 2081 (1.7%) | 2154 (1.8%) | 1889 (1.5%) | ||
Neoplasms | 6000 (4.9%) | 6242 (5.1%) | 6561 (5.4%) | 6863 (5.6%) | 7376 (6.0%) | 8012 (6.6%) | 7499 (6.1%) | ||
Others | 17,243 (14.1%) | 17,309 (14.2%) | 17,401 (14.2%) | 17,481 (14.3%) | 17,727 (14.5%) | 18,055 (14.8%) | 16,635 (13.6%) | ||
85–95 | Circulatory | 19,551 (16.0%) | 19,613 (16.0%) | 19,621 (16.0%) | 19,722 (16.1%) | 19,894 (16.3%) | 20,054 (16.4%) | 18,409 (15.1%) | |
Respiratory | 11,504 (9.4%) | 11,832 (9.7%) | 12,396 (10.1%) | 13,119 (10.7%) | 14,295 (11.7%) | 16,263 (13.3%) | 16,891 (13.8%) | ||
CKD | 2252 (1.8%) | 2318 (1.9%) | 2341 (1.9%) | 2399 (2.0%) | 2490 (2.0%) | 2652 (2.2%) | 2402 (2.0%) | ||
Neoplasms | 5811 (4.8%) | 6005 (4.9%) | 6311 (5.2%) | 6662 (5.4%) | 7198 (5.9%) | 8045 (6.6%) | 7598 (6.2%) | ||
Others | 23,004 (18.8%) | 23,009 (18.8%) | 23,212 (19.0%) | 23,451 (19.2%) | 23,725 (19.4%) | 24,218 (19.8%) | 22,415 (18.3%) | ||
Female | 65–75 | Circulatory | 2909 (2.4%) | 2887 (2.4%) | 2902 (2.4%) | 2933 (2.4%) | 2924 (2.4%) | 2996 (2.4%) | 2758 (2.3%) |
Respiratory | 1747 (1.4%) | 1741 (1.4%) | 1783 (1.5%) | 1840 (1.5%) | 1990 (1.6%) | 2223 (1.8%) | 2264 (1.9%) | ||
CKD | 299 (0.2%) | 310 (0.3%) | 311 (0.3%) | 313 (0.3%) | 335 (0.3%) | 343 (0.3%) | 302 (0.2%) | ||
Neoplasms | 1967 (1.6%) | 2024 (1.7%) | 2103 (1.7%) | 2241 (1.8%) | 2377 (1.9%) | 2547 (2.1%) | 2447 (2.0%) | ||
Others | 4193 (3.4%) | 4232 (3.5%) | 4263 (3.5%) | 4329 (3.5%) | 4371 (3.6%) | 4462 (3.6%) | 4111 (3.4%) | ||
75–85 | Circulatory | 11,033 (9.0%) | 11,051 (9.0%) | 11,105 (9.1%) | 11,143 (9.1%) | 11,158 (9.1%) | 11,194 (9.2%) | 10,387 (8.5%) | |
Respiratory | 5611 (4.6%) | 5704 (4.7%) | 5870 (4.8%) | 6195 (5.1%) | 6628 (5.4%) | 7495 (6.1%) | 8043 (6.6%) | ||
CKD | 1087 (0.9%) | 1108 (0.9%) | 1106 (0.9%) | 1178 (1.0%) | 1187 (1.0%) | 1236 (1.0%) | 1106 (0.9%) | ||
Neoplasms | 3631 (3.0%) | 3793 (3.1%) | 4013 (3.3%) | 4267 (3.5%) | 4635 (3.8%) | 5046 (4.1%) | 4845 (4.0%) | ||
Others | 13,841 (11.3%) | 13,866 (11.3%) | 13,955 (11.4%) | 14,092 (11.5%) | 14,224 (11.6%) | 14,366 (11.7%) | 13,278 (10.9%) | ||
85–95 | Circulatory | 25,739 (21.0%) | 25,771 (21.1%) | 25,897 (21.2%) | 25,975 (21.2%) | 26,249 (21.5%) | 26,392 (21.6%) | 24,882 (20.3%) | |
Respiratory | 11,502 (9.4%) | 11,864 (9.7%) | 12,365 (10.1%) | 13,070 (10.7%) | 14,274 (11.7%) | 16,441 (13.4%) | 17,989 (14.7%) | ||
CKD | 1847 (1.5%) | 1888 (1.5%) | 1969 (1.6%) | 2024 (1.7%) | 2110 (1.7%) | 2278 (1.9%) | 2124 (1.7%) | ||
Neoplasms | 4082 (3.3%) | 4318 (3.5%) | 4643 (3.8%) | 5018 (4.1%) | 5670 (4.6%) | 6395 (5.2%) | 6309 (5.2%) | ||
Others | 29,713 (24.3%) | 29,855 (24.4%) | 30,091 (24.6%) | 30,140 (24.6%) | 30,713 (25.1%) | 31,000 (25.3%) | 28,844 (23.6%) | ||